The biosimilars industry is increasingly focusing its attention on emerging markets, a move that offers both enormous potential and challenges. FirstView’s Biosimilars in Emerging Markets: Opportunities, Challenges and Critical Success Factors report offers timely insight into the right strategies and approaches for success.
Biosimilars in Emerging Markets: Opportunities, Challenges and Critical Success Factors pulls back the curtain on emerging markets to reveal the greatest challenges and opportunities for biosimilars. From critical components to success to which emerging markets are the most important for growth, get the information you need so your company can differentiate itself in this highly competitive market.
Gain specific insights on key emerging markets in Brazil, China, India, Mexico, Poland, Russia and Turkey. Learn which stakeholders hold the power as well as critical success factors.
“For the emerging markets, I think the number one success factor is to have a very good local partner. We really count on that as a key thing.”
Don Stewart, CEO, PlantForm.
“I think there is a need for more biologics in emerging markets that can treat Western style diseases. Drugs like mAbs to treat cancer and rheumatoid arthritis, insulin to treat diabetes and interferon-beta to treat MS, are now needed more than ever. Access to these products in emerging markets is low, and biosimilars have the potential to be able to improve access.”
Carsten Brockmeyer, CEO of Formycon
“My prediction is that formal biosimilar guidelines will be in place in the Russian market within the next 12 18 months. My company [Biocad] is leading an industry group which has developed a set of biosimilar guidelines. These guidelines have similar requirements to the EMA and WHO guidelines, and have been submitted to the Russian Ministry of Health for review.”
Roman Ivanov, VP R&D, CJSC Biocad
“A quality product is completely essential. You need a robust data package, a high quality drug master file. That is the key to success in Brazil, and many other emerging markets.”
Eduardo Cruz; CEO, Axis Biotec.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved